Compare ALEMBIC PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ABBOTT INDIA ALEMBIC PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 15.2 43.1 35.3% View Chart
P/BV x 3.5 12.3 28.3% View Chart
Dividend Yield % 1.1 0.6 194.9%  

Financials

 ALEMBIC PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
ABBOTT INDIA
Mar-18
ALEMBIC PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs6646,110 10.9%   
Low Rs4123,996 10.3%   
Sales per share (Unadj.) Rs208.71,552.2 13.4%  
Earnings per share (Unadj.) Rs31.0188.8 16.4%  
Cash flow per share (Unadj.) Rs37.1196.4 18.9%  
Dividends per share (Unadj.) Rs5.5055.00 10.0%  
Dividend yield (eoy) %1.01.1 93.9%  
Book value per share (Unadj.) Rs144.2796.6 18.1%  
Shares outstanding (eoy) m188.5221.25 887.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.3 79.2%   
Avg P/E ratio x17.426.8 64.9%  
P/CF ratio (eoy) x14.525.7 56.4%  
Price / Book Value ratio x3.76.3 58.8%  
Dividend payout %17.729.1 60.9%   
Avg Mkt Cap Rs m101,461107,376 94.5%   
No. of employees `000NA3.3 0.0%   
Total wages/salary Rs m7,4673,937 189.7%   
Avg. sales/employee Rs ThNM9,929.3-  
Avg. wages/employee Rs ThNM1,185.1-  
Avg. net profit/employee Rs ThNM1,207.7-  
INCOME DATA
Net Sales Rs m39,34732,985 119.3%  
Other income Rs m941,170 8.0%   
Total revenues Rs m39,44134,155 115.5%   
Gross profit Rs m8,7365,245 166.6%  
Depreciation Rs m1,152162 711.7%   
Interest Rs m18438 481.9%   
Profit before tax Rs m7,4936,215 120.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5682,203 71.2%   
Profit after tax Rs m5,8444,012 145.7%  
Gross profit margin %22.215.9 139.6%  
Effective tax rate %20.935.4 59.0%   
Net profit margin %14.912.2 122.1%  
BALANCE SHEET DATA
Current assets Rs m19,57722,655 86.4%   
Current liabilities Rs m14,8966,681 223.0%   
Net working cap to sales %11.948.4 24.6%  
Current ratio x1.33.4 38.8%  
Inventory Days Days9065 138.5%  
Debtors Days Days4529 155.6%  
Net fixed assets Rs m27,097835 3,243.3%   
Share capital Rs m377213 177.4%   
"Free" reserves Rs m26,81116,715 160.4%   
Net worth Rs m27,18816,928 160.6%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77824,162 197.7%  
Interest coverage x41.7163.7 25.5%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.81.4 60.3%   
Return on assets %12.616.8 75.3%  
Return on equity %21.523.7 90.7%  
Return on capital %23.636.9 63.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,453369 5,278.3%   
Fx outflow Rs m6,0653,807 159.3%   
Net fx Rs m13,388-3,438 -389.4%   
CASH FLOW
From Operations Rs m8,1201,527 531.7%  
From Investments Rs m-7,556-2,148 351.7%  
From Financial Activity Rs m590-1,024 -57.6%  
Net Cashflow Rs m1,153-1,646 -70.1%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 7.9 36.7%  
FIIs % 9.1 0.1 9,100.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.1 81.3%  
Shareholders   49,328 18,270 270.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Up 0.4% (Market Updates)

Sep 16, 2019 | Updated on Sep 16, 2019

ABBOTT INDIA share price has hit an all time high at Rs 10,015 (up 1.5%). The BSE HEALTHCARE Index is up by 0.4%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.5%) and PROCTER & GAMBLE HEALTH (up 1.2%). The top losers include NATCO PHARMA (down 0.2%) and BIOCON (down 0.2%).

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 16, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS